Cardinal Health Sees Stock Price Target Raises after Q4 Earnings

CAH drew a wave of price-target increases after reporting fiscal fourth-quarter and full-year 2026 results on August 11, with Mizuho and Evercore ISI among the firms raising their targets on the stock. The moves reflect an improved analyst outlook following a quarter that beat expectations on several fronts.

Cardinal Health's fiscal Q4 revenue came in at roughly $63.7 billion, up about 6% year over year, while non-GAAP diluted EPS rose about 40% to $2.91. For the full fiscal year, revenue reached approximately $254.2 billion, up 14% from fiscal 2025. The company also issued fiscal 2027 adjusted EPS guidance in the $12.40-$12.60 range, giving analysts a fresh data point to model against as they update their price targets.

The breadth of the target increases, spanning multiple firms rather than a single outlier call, could suggest a broader analyst consensus is forming around Cardinal Health's execution on margin improvement and cost discipline. That said, price-target revisions tend to follow the earnings print rather than lead it, so the more informative signal may be whether Cardinal Health can sustain this pace of EPS growth into fiscal 2027 rather than the specific dollar targets themselves.

Investors will likely watch upcoming commentary from Cardinal Health's management on segment performance and cost-cutting initiatives to gauge whether the raised targets are grounded in durable operational gains or reflect optimism embedded in a single strong quarter.

Related Stocks

• CAH